SEC Comment Letter 0000000000-23-002260 to Incannex Healthcare Inc. (IXHL)
Incannex Healthcare Inc.
Date: March 8, 2023 · CIK: 0001873875 · Accession: 0000000000-23-002260
AI Filing Summary & Sentiment
File numbers found in text: 333-270218
Letter
United States securities and exchange commission logo March 8, 2023 Joel Latham Managing Director & CEO Incannex Healthcare Ltd Suite 105, 8 Century Circuit Norwest, NSW 2153, Australia Re:Incannex Healthcare Ltd Registration Statement on Form F-3 Filed March 2, 2023 File No. 333-270218 Dear Joel Latham: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew Reilly
Show Raw Text
United States securities and exchange commission logo
March 8, 2023
Joel Latham
Managing Director & CEO
Incannex Healthcare Ltd
Suite 105, 8 Century Circuit
Norwest, NSW 2153, Australia
Re:Incannex Healthcare Ltd
Registration Statement on Form F-3
Filed March 2, 2023
File No. 333-270218
Dear Joel Latham:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Andrew Reilly